10-Q: Mosaic ImmunoEngineering Faces Going Concern Doubt

Mosaic ImmunoEngineering, a development-stage biotech, reported significant financial challenges, including a going concern warning and the expiration of a key acquisition agreement.

Summary

• Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on immunotherapies for cancer, with no revenues generated to date.
• The company reported a net loss of $172,028 for the three months ended June 30, 2025, and $353,348 for the six months ended June 30, 2025.
• Cash and cash equivalents stood at $53,583 as of June 30, 2025, a significant decrease from $115,019 at December 31, 2024.
• Total liabilities increased to $7,199,221 as of June 30, 2025, from $6,929,785 at December 31, 2024.
• The accumulated deficit reached $9,191,668 as of June 30, 2025.
• The binding term sheet with Oncotelic Therapeutics, Inc. for the acquisition of cancer therapies and AI technologies, valued at up to $30 million, expired on June 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, as current cash will not satisfy operational and capital requirements for the next twelve months.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, with a 'going concern' warning, critically low cash reserves, increasing liabilities, and the failure of a key strategic acquisition. Management resignations further compound the negative outlook, indicating a high risk of operational cessation.

Positives

• Net loss decreased to $353,348 for the six months ended June 30, 2025, compared to $582,209 for the same period in 2024, primarily due to reduced operating expenses.
• Research and development expenses decreased by $96,209 for the six months ended June 30, 2025, compared to the prior year period, reflecting cost management.
• General and administrative expenses decreased by $123,231 for the six months ended June 30, 2025, compared to the prior year period, mainly due to reduced payroll and related costs.
• The company earned $14,000 in other income from a Master Services Agreement with Oncotelic for advisory services during the six months ended June 30, 2025.

Negatives

• The company has not generated any revenues to date.
• Cash and cash equivalents significantly declined to $53,583 as of June 30, 2025, from $115,019 at December 31, 2024.
• Total liabilities increased to $7,199,221 as of June 30, 2025.
• The accumulated deficit grew to $9,191,668 as of June 30, 2025.
• The binding term sheet with Oncotelic Therapeutics, Inc., a key strategic initiative, expired on June 30, 2025, without a definitive agreement.
• The company's ability to continue operations is highly dependent on raising additional capital, with no current arrangements for financing.
• Three key management and board members, including the EVP, CFO, resigned effective August 15 and August 18, 2025.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient cash and lack of revenues.
• Inability to raise additional capital will delay or cease business operations, potentially leading to the company ceasing operations altogether.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• Debt financing, if obtained, may involve significant cash payment obligations and restrictive covenants.
• Disruptions from COVID-19, broad-based inflation, and potential recession may adversely impact the ability to fund future operations.
• The company has limited technologies and has scaled back development programs due to insufficient funds.
• Accrued compensation and consulting fees represent significant liabilities that may require cash payments.

Future Outlook

Management anticipates that current cash and cash equivalents will not satisfy operational and capital requirements through the next twelve months from the filing date. The company plans to continue funding losses and future needs through cash on hand and potential future equity and/or debt offerings, acknowledging significant challenges in raising capital due to market conditions and limited technologies. The inability to obtain additional capital will delay business operations, and insufficient funds may lead to the cessation of operations altogether. The binding term sheet with Oncotelic Therapeutics, Inc. expired, impacting the company's strategy to establish a new product pipeline.

Management Comments

• "Our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations."
• "We anticipate, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Quarterly Report on Form 10-Q."
• "Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations."
• "Any additional equity financing may involve substantial dilution to our then existing stockholders."
• "If we continue to have insufficient funds, we may be required to cease our operations altogether."

Industry Context

Mosaic ImmunoEngineering operates in the highly capital-intensive and risky development-stage biotechnology sector, specifically focusing on immunotherapies for cancer. The expiration of the Oncotelic binding term sheet means the company has lost a potential avenue to establish a new product pipeline and leverage AI technologies, which is a significant setback in an industry where pipeline depth and strategic partnerships are crucial for long-term viability and investor confidence. The company's current financial state, characterized by minimal cash and a going concern warning, places it at a severe disadvantage compared to more established or better-funded biotech peers.

Comparison to Industry Standards

• Mosaic ImmunoEngineering's status as a development-stage company with no revenue is typical for early-stage biotech firms, but its cash position of $53,583 is critically low compared to industry norms, where companies often raise tens or hundreds of millions of dollars to fund clinical trials and R&D.
• The accumulated deficit of over $9 million is common for development-stage biotechs, but without a clear path to significant capital infusion or a robust clinical pipeline, it signals a high risk.
• The expiration of the Oncotelic binding term sheet, which aimed to acquire clinical-stage assets and AI technology, represents a failure to execute a critical strategic move. Successful biotech companies frequently engage in licensing or M&A to build out their pipelines, and the inability to close this deal leaves Mosaic with a very limited and early-stage portfolio (MIE-101 focus).
• The company's R&D spending of $31,809 for six months is extremely low for a biotech company aiming to advance immunotherapies, especially when compared to peers that spend millions or tens of millions annually on drug development and clinical trials. This indicates a severe lack of funding for meaningful progress.
• The explicit 'going concern' warning is a red flag, indicating that the company's financial viability is in question, a situation that is highly atypical for a healthy, progressing biotech firm and usually precedes significant restructuring or failure.

Management Changes

Legal Proceedings

• The company is not involved in any litigation as of June 30, 2025.
• An unresolved dispute from August 2009 exists regarding 5,690 shares of common stock held in escrow related to the Crossflo acquisition, where the company seeks their return due to incurred damages. Management believes the resolution will not result in a material obligation.

Related Party Transactions

• Accrued $264,375 in consulting fees to co-founders (Dr. Steinmetz, Dr. Pokorski, Dr. Fiering), which are deferred and tied to future financing.
• Three members of the Board of Directors participated in the May 2021 convertible note offering, investing $225,000 in aggregate.
• Five members of the Board of Directors participated in the February 2022 convertible note offering, investing $155,000 in aggregate.
• Steven King, President and CEO, is a shareholder (<1% ownership) and paid advisor of Oncotelic Therapeutics, Inc.
• The company repaid a $70,000 principal and $6,214 accrued interest convertible note to Oncotelic Therapeutics, Inc. on December 12, 2024.

Stakeholder Impact

• Shareholders face significant risk of substantial dilution from future equity raises and the potential for complete loss of investment if the company ceases operations.
• Employees may face job insecurity due to the company's severe financial distress and reduced time commitment by certain personnel.
• Creditors, particularly holders of convertible notes and those with accrued compensation/consulting fees, face uncertainty regarding repayment given the company's limited liquidity and going concern warning.
• Potential partners and licensors may be hesitant to engage with the company given its financial instability and inability to close prior strategic deals.

Next Steps

• Identify new product candidates and license or acquire those rights.
• Raise significant additional capital through equity and/or debt offerings to support research and development efforts, compensation, and hiring.
• Negotiate and secure new strategic partnerships or acquisitions to build a product pipeline, following the expiration of the Oncotelic binding term sheet.

Key Dates

Recommendation

The company is in a precarious financial position, explicitly stating 'substantial doubt' about its ability to continue as a going concern. Cash reserves are critically low ($53,583), insufficient to cover operations for the next 12 months. A key strategic acquisition agreement with Oncotelic Therapeutics, Inc. expired, leaving the company with a very limited pipeline and no clear path to significant revenue generation. Furthermore, recent resignations of key management and board members signal instability. The high accumulated deficit and reliance on uncertain future capital raises, which would likely cause significant dilution, make the investment highly speculative with a high risk of total loss. There are no clear positive catalysts to offset these severe risks.

Keywords

Immunotherapy, Cancer treatment, Biotechnology, Development-stage, SEC filing, 10-Q, Going concern, Capital raise, Oncotelic, MIE-101, Oncology